Anhui Anke Biotechnology (Group) Past Earnings Performance
Past criteria checks 5/6
Anhui Anke Biotechnology (Group) has been growing earnings at an average annual rate of 31.6%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 13% per year. Anhui Anke Biotechnology (Group)'s return on equity is 21.4%, and it has net margins of 30%.
Key information
31.6%
Earnings growth rate
31.1%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 13.0% |
| Return on equity | 21.4% |
| Net Margin | 30.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Anhui Anke Biotechnology (Group) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,928 | 879 | 1,078 | 256 |
| 31 Dec 23 | 2,866 | 847 | 1,050 | 255 |
| 30 Sep 23 | 2,646 | 763 | 954 | 211 |
| 30 Jun 23 | 2,538 | 755 | 900 | 207 |
| 31 Mar 23 | 2,392 | 716 | 861 | 172 |
| 01 Jan 23 | 2,331 | 703 | 877 | 166 |
| 30 Sep 22 | 2,328 | 372 | 862 | 174 |
| 30 Jun 22 | 2,280 | 307 | 911 | 168 |
| 31 Mar 22 | 2,217 | 254 | 941 | 163 |
| 31 Dec 21 | 2,169 | 207 | 947 | 167 |
| 30 Sep 21 | 2,096 | 489 | 944 | 154 |
| 30 Jun 21 | 1,959 | 441 | 900 | 134 |
| 31 Mar 21 | 1,871 | 403 | 867 | 142 |
| 31 Dec 20 | 1,701 | 359 | 795 | 129 |
| 30 Sep 20 | 1,702 | 167 | 781 | 117 |
| 30 Jun 20 | 1,661 | 140 | 776 | 119 |
| 31 Mar 20 | 1,681 | 140 | 785 | 118 |
| 31 Dec 19 | 1,713 | 124 | 816 | 120 |
| 30 Sep 19 | 1,607 | 289 | 799 | 118 |
| 30 Jun 19 | 1,598 | 280 | 799 | 112 |
| 31 Mar 19 | 1,529 | 270 | 784 | 93 |
| 31 Dec 18 | 1,462 | 263 | 744 | 87 |
| 30 Sep 18 | 1,382 | 317 | 654 | 71 |
| 30 Jun 18 | 1,276 | 292 | 564 | 99 |
| 31 Mar 18 | 1,177 | 290 | 503 | 86 |
| 31 Dec 17 | 1,096 | 278 | 465 | 70 |
| 30 Sep 17 | 1,009 | 249 | 451 | 47 |
| 30 Jun 17 | 941 | 228 | 466 | 0 |
| 31 Mar 17 | 878 | 209 | 417 | 0 |
| 31 Dec 16 | 849 | 197 | 402 | 0 |
| 30 Sep 16 | 751 | 169 | 355 | 0 |
| 30 Jun 16 | 696 | 160 | 318 | 0 |
| 31 Mar 16 | 671 | 148 | 311 | 0 |
| 31 Dec 15 | 636 | 136 | 298 | 0 |
| 30 Sep 15 | 629 | 137 | 286 | 0 |
| 30 Jun 15 | 609 | 127 | 284 | 0 |
| 31 Mar 15 | 579 | 115 | 276 | 0 |
| 31 Dec 14 | 542 | 110 | 257 | 0 |
| 30 Sep 14 | 509 | 107 | 238 | 0 |
| 30 Jun 14 | 472 | 99 | 221 | 0 |
| 31 Mar 14 | 448 | 94 | 214 | 0 |
| 31 Dec 13 | 430 | 90 | 208 | 0 |
| 30 Sep 13 | 394 | 87 | 191 | 0 |
| 30 Jun 13 | 377 | 80 | 186 | 0 |
Quality Earnings: 300009 has high quality earnings.
Growing Profit Margin: 300009's current net profit margins (30%) are higher than last year (29.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300009's earnings have grown significantly by 31.6% per year over the past 5 years.
Accelerating Growth: 300009's earnings growth over the past year (22.8%) is below its 5-year average (31.6% per year).
Earnings vs Industry: 300009 earnings growth over the past year (22.8%) exceeded the Biotechs industry -3.2%.
Return on Equity
High ROE: 300009's Return on Equity (21.4%) is considered high.